Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 1066-1072

  Oh, Sung Yong ^a   Jeong, Chi Young ^b   Hong, Soon Chan ^b   Kim, Tae Hyo ^b   Ha, Chang Yoon ^b   Kim, Hyun Jin ^b   Lee, Gyeong Won ^b,c   Hwang, In Gyu ^d   Jang, Joung Soon ^d   Kwon, Hyuk Chan ^a   Kang, Jung Hun ^b,c,e  

^a Dong A University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Gyeongnam Regional Cardiocerebrovascular Disease Center   (South Korea)

^d Chung Ang University   (South Korea)

^e Gyeongsang National University   (South Korea)

Author keywords

5 fluorouracil; Biliary tract neoplasm; Gemcitabine; Salvage treatment

Indexed keywords

ALBUMIN; FLUOROURACIL; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL MENINGITIS; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; EPISTAXIS; EXTRAHEPATIC CHOLANGIOCARCINOMA; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GALLBLADDER CANCER; HUMAN; HYPERBILIRUBINEMIA; INFECTION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PRURITUS; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UREMIA; VOMITING; BILIARY TRACT TUMOR; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG RESISTANCE; MIDDLE AGED; PROGNOSIS; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84655171716     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9417-3     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, Choi JS, Kim WC, Lee TY, Yoo CI, Bae JM, Kim ON, Chung W, Kong IS, Lee JS (2009) Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 41:122-131
3. Patel T (2002) Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2:10
4. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593-600
5. Falkson G, MacIntyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54:965-969
6. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP (1998) Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9:653-656
7. Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T, Cunningham D (1995) Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31 A: 1594-1598
8. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK (2003) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 14:1115-1120
9. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK (2007) Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 60:321-328
10. Park SH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH (2006) Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 106:361-365
11. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91:1769-1774
12. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103:111-118
13. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K (2006) A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339-1346
14. Lee GW, Kang JH, Kim HG, Lee JS, Jang JS (2006) Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 29:127-131
15. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104:2753-2758
16. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307-1312
17. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
18. Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. Oncologist 13:415-423
19. Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ (2009) Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabinepretreated pancreatic and biliary tract cancer. Am J Clin Oncol 32:348-352
20. Capdevila J, Ramos FJ, Macarulla T, Elez E, Ruiz-Echarri M, Perez-Garcia J, Tabernero J (2009) Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. Curr Opin Oncol 21:374-380
21. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069-3074
22. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV (2009) Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol
23. Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G, Conte P (2010) Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 102:68-72